The Centralized Protocol and Data Management Unit (CPDMU) is a Cancer Center Shared Resource widely used by members performing clinical and translational trials. The CPDMU, which was formerly known as the Clinical Trials Office at the last CCSG review, plays a central role in clinical/translational research in the Cancer Center. The primary mission of the CPDMU is to provide the necessary components and support to conduct high-quality clinical cancer research at the Cancer Center at the University of Nebraska Medical Center, as well as UNMC affiliated hospitals (The Nebraska Medical Center, Children's Hospital Medical Center, Veterans Administration Hospital), and at Cancer Center Affiliate sites across the state. The CPDMU provides a centralized resource to facilitate the development, conduct, quality assurance monitoring, compliance with regulatory agency requirements, and evaluation of clinical research at the Cancer Center. All cancer related research proposals flow through the protocol development process established and administered by the CPDMU and are subsequently sent for review to the Protocol Review and Monitoring System (PRMS), the PRMS Scientific Review Committee (SRC) and to the IRB. The CPDMU database of clinical trials also provides support for the PRMS SRC and Audit Committee (AC) and for the Data and Safety Monitoring Committee (DSMC).

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA036727-27
Application #
8566900
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-08-01
Budget End
2014-07-31
Support Year
27
Fiscal Year
2013
Total Cost
$64,482
Indirect Cost
$21,060
Name
University of Nebraska Medical Center
Department
Type
DUNS #
168559177
City
Omaha
State
NE
Country
United States
Zip Code
68198
Xie, Shuwei; Bahl, Kriti; Reinecke, James B et al. (2016) The endocytic recycling compartment maintains cargo segregation acquired upon exit from the sorting endosome. Mol Biol Cell 27:108-26
Hanson, Ryan L; Brown, Roger B; Steele, Maria M et al. (2016) Identification of FRA-1 as a novel player in pancreatic cancer in cooperation with a MUC1: ERK signaling axis. Oncotarget 7:39996-40011
Hill, Tanner K; Mohs, Aaron M (2016) Image-guided tumor surgery: will there be a role for fluorescent nanoparticles? Wiley Interdiscip Rev Nanomed Nanobiotechnol 8:498-511
Pai, Priya; Rachagani, Satyanarayana; Dhawan, Punita et al. (2016) MUC4 is negatively regulated through the Wnt/β-catenin pathway via the Notch effector Hath1 in colorectal cancer. Genes Cancer 7:154-68
Spagnol, Gaelle; Kieken, Fabien; Kopanic, Jennifer L et al. (2016) Structural Studies of the Nedd4 WW Domains and Their Selectivity for the Connexin43 (Cx43) Carboxyl Terminus. J Biol Chem 291:7637-50
Hill, Tanner K; Davis, Amanda L; Wheeler, Frances B et al. (2016) Development of a Self-Assembled Nanoparticle Formulation of Orlistat, Nano-ORL, with Increased Cytotoxicity against Human Tumor Cell Lines. Mol Pharm 13:720-8
Wuebben, Erin L; Wilder, Phillip J; Cox, Jesse L et al. (2016) SOX2 functions as a molecular rheostat to control the growth, tumorigenicity and drug responses of pancreatic ductal adenocarcinoma cells. Oncotarget 7:34890-906
Kelkar, Sneha S; Hill, Tanner K; Marini, Frank C et al. (2016) Near infrared fluorescent nanoparticles based on hyaluronic acid: Self-assembly, optical properties, and cell interaction. Acta Biomater 36:112-21
Marr, Alissa S; Zhang, Chi; Ganti, Apar Kishor (2016) Resected small cell lung cancer-time for more? J Thorac Dis 8:E755-7
Fox, Raymond G; Lytle, Nikki K; Jaquish, Dawn V et al. (2016) Image-based detection and targeting of therapy resistance in pancreatic adenocarcinoma. Nature 534:407-11

Showing the most recent 10 out of 1236 publications